The correct schedule, not the shortest one
Shorter courses get the attention, and for many patients fewer visits genuinely is better — less travel, less time off work, less disruption. But ‘fewer fractions’ is not the goal. The goal is the correct schedule: the dose per fraction, total dose, and delivery technique that control the disease at the lowest cost in normal-tissue injury for this person.
Those are different questions, and they can point in opposite directions. Dividing dose into smaller fractions is what spares late-responding normal tissue — the tissue whose injury shows up years later, in the survivorship clinic, long after the cancer is gone. Compressing a course trades some of that sparing for convenience. Sometimes that trade is clearly right. Sometimes it is clearly wrong. Deciding which, for whom, is the work.
The levers we study
- Temporal fractionation. Dose per fraction and total dose, set against the α/β ratio of the tumour and of the normal tissue in the field.
- Spatial fractionation. Deliberately non-uniform dose — GRID, lattice, minibeam — as a way to spare normal tissue within the treated volume. The evidence here is early and largely preclinical or single-arm, and we say so.
- Delivery technique. Superficial, conformal, stereotactic or image-guided: which geometry puts the least dose where it is not wanted.
- Goals of care. A patient with a decade of life ahead and a patient managing symptoms in their last year are not solving the same problem, and should not automatically be offered the same schedule.
- Burden of treatment. Travel, cost, time away from work and family are clinical variables, not soft ones. A regimen a patient cannot complete is not the better regimen.
- Measured late effects. Every claim about normal-tissue sparing is a claim about years, and is only answerable by longitudinal follow-up.
Options and choices, patient by patient
The practical output of this work is not a single recommended schedule. It is a clearer set of options, each with an honest account of what it costs and what it buys, so a clinician and a patient can choose between them rather than be handed one.
That is also why the survivorship clinic matters to an innovation programme. Without long follow-up, a schedule can look excellent for five years and reveal its price in the sixth.